TD Cowen on Arrowhead Pharma (ARWR): 'We remain at Buy as the pipeline remains robust'
Tweet Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating on Arrowhead Pharma (NASDAQ: ARWR).The analyst comments "WVE released additional data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
